Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.94
NAS:VRTX's Cash-to-Debt is ranked lower than
66% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:VRTX: 2.94 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:VRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66  Med: 2.45 Max: 26.61
Current: 2.94
0.66
26.61
Equity-to-Asset 0.51
NAS:VRTX's Equity-to-Asset is ranked lower than
66% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:VRTX: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:VRTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.51 Max: 0.95
Current: 0.51
-0.02
0.95
Debt-to-Equity 0.34
NAS:VRTX's Debt-to-Equity is ranked lower than
55% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:VRTX: 0.34 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:VRTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -39.45  Med: 0.42 Max: 9.45
Current: 0.34
-39.45
9.45
Debt-to-EBITDA 1.41
NAS:VRTX's Debt-to-EBITDA is ranked higher than
59% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:VRTX: 1.41 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:VRTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.04  Med: -0.46 Max: 11.79
Current: 1.41
-2.04
11.79
Interest Coverage 4.78
NAS:VRTX's Interest Coverage is ranked lower than
90% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:VRTX: 4.78 )
Ranked among companies with meaningful Interest Coverage only.
NAS:VRTX' s Interest Coverage Range Over the Past 10 Years
Min: 0.12  Med: 2.81 Max: 4.78
Current: 4.78
0.12
4.78
Piotroski F-Score: 8
Altman Z-Score: 13.71
Beneish M-Score: -2.76
WACC vs ROIC
14.85%
41.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 16.16
NAS:VRTX's Operating Margin % is ranked higher than
85% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:VRTX: 16.16 )
Ranked among companies with meaningful Operating Margin % only.
NAS:VRTX' s Operating Margin % Range Over the Past 10 Years
Min: -602.63  Med: -84.82 Max: 16.16
Current: 16.16
-602.63
16.16
Net Margin % 12.19
NAS:VRTX's Net Margin % is ranked higher than
83% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:VRTX: 12.19 )
Ranked among companies with meaningful Net Margin % only.
NAS:VRTX' s Net Margin % Range Over the Past 10 Years
Min: -630.27  Med: -90.57 Max: 12.19
Current: 12.19
-630.27
12.19
ROE % 20.49
NAS:VRTX's ROE % is ranked higher than
93% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:VRTX: 20.49 )
Ranked among companies with meaningful ROE % only.
NAS:VRTX' s ROE % Range Over the Past 10 Years
Min: -180.27  Med: -57.99 Max: 20.49
Current: 20.49
-180.27
20.49
ROA % 9.09
NAS:VRTX's ROA % is ranked higher than
90% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:VRTX: 9.09 )
Ranked among companies with meaningful ROA % only.
NAS:VRTX' s ROA % Range Over the Past 10 Years
Min: -58.14  Med: -27.38 Max: 9.09
Current: 9.09
-58.14
9.09
ROC (Joel Greenblatt) % 48.86
NAS:VRTX's ROC (Joel Greenblatt) % is ranked higher than
91% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:VRTX: 48.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:VRTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1092.55  Med: -102.98 Max: 110.77
Current: 48.86
-1092.55
110.77
3-Year Revenue Growth Rate 8.90
NAS:VRTX's 3-Year Revenue Growth Rate is ranked higher than
59% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:VRTX: 8.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:VRTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.5  Med: 10.95 Max: 129.4
Current: 8.9
-32.5
129.4
3-Year EPS without NRI Growth Rate -41.00
NAS:VRTX's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:VRTX: -41.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:VRTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41  Med: 10.3 Max: 94.9
Current: -41
-41
94.9
GuruFocus has detected 3 Warning Signs with Vertex Pharmaceuticals Inc $NAS:VRTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:VRTX's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

VRTX Guru Trades in Q4 2016

Steven Cohen 887,000 sh (New)
Paul Tudor Jones 9,611 sh (New)
Manning & Napier Advisors, Inc 2,126,020 sh (+1391.53%)
Jeremy Grantham 100,000 sh (+98.81%)
Vanguard Health Care Fund 13,230,341 sh (+2.44%)
Ken Fisher 5,168 sh (unchged)
Jeremy Grantham 100,000 sh (unchged)
David Carlson 270,000 sh (unchged)
Joel Greenblatt Sold Out
John Burbank Sold Out
Pioneer Investments 1,226,158 sh (-0.40%)
Eaton Vance Worldwide Health Sciences Fund 226,707 sh (-15.97%)
» More
Q1 2017

VRTX Guru Trades in Q1 2017

George Soros 3,600 sh (New)
Jim Simons 40,117 sh (New)
Pioneer Investments 1,518,822 sh (+23.87%)
Ken Fisher 5,213 sh (+0.87%)
David Carlson 270,000 sh (unchged)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 13,014,973 sh (-1.63%)
Manning & Napier Advisors, Inc 1,764,419 sh (-17.01%)
Steven Cohen 271,663 sh (-69.37%)
Eaton Vance Worldwide Health Sciences Fund 180,739 sh (-20.28%)
» More
Q2 2017

VRTX Guru Trades in Q2 2017

Ray Dalio 18,673 sh (New)
Joel Greenblatt 182,515 sh (New)
Ken Fisher 5,946 sh (+14.06%)
Eaton Vance Worldwide Health Sciences Fund 180,739 sh (unchged)
George Soros Sold Out
Manning & Napier Advisors, Inc 1,631,126 sh (-7.55%)
Vanguard Health Care Fund 11,626,983 sh (-10.66%)
Pioneer Investments 1,326,757 sh (-12.65%)
David Carlson 230,000 sh (-14.81%)
Jim Simons 21,700 sh (-45.91%)
Steven Cohen 11,141 sh (-95.90%)
» More
2017

VRTX Guru Trades in 2017

Spiros Segalas 2,068,985 sh (+216.10%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -10.66%0.34%$107.45 - $135.53 $ 154.7029%11,626,983
Joel Greenblatt 2017-06-30 New Buy0.33%$107.45 - $135.53 $ 154.7029%182,515
Ken Fisher 2017-06-30 Add 14.06%$107.45 - $135.53 $ 154.7029%5,946
George Soros 2017-06-30 Sold Out 0.01%$107.45 - $135.53 $ 154.7029%0
Vanguard Health Care Fund 2017-03-31 Reduce -1.63%0.04%$74.89 - $109.35 $ 154.7076%13,014,973
Ken Fisher 2017-03-31 Add 0.87%$74.89 - $109.35 $ 154.7076%5,213
George Soros 2017-03-31 New Buy0.01%$74.89 - $109.35 $ 154.7076%3,600
Vanguard Health Care Fund 2016-12-31 Add 2.44%0.06%$72.02 - $95.36 $ 154.7090%13,230,341
Joel Greenblatt 2016-12-31 Sold Out 0.08%$72.02 - $95.36 $ 154.7090%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ALXN, LSE:SHP, XSWX:ATLN, NAS:REGN, ASX:CSL, NAS:INCY, XKRX:207940, XMCE:GRF.P, NAS:BMRN, XKRX:068270, SZSE:002252, OCSE:NZYM B, OCSE:GEN, XBRU:UCB, NAS:ALNY, NAS:KITE, NAS:JAZZ, NAS:BIIB, NAS:ALKS, HKSE:01177 » details
Traded in other countries:VRTX.Austria, VX1.Germany, VRTX.Mexico, VRTX.Switzerland, 0QZU.UK,
Headquarter Location:USA
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. The firm's key drugs are Kalydeco and Orkambi for cystic fibrosis and has also several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, and influenza.

Top Ranked Articles about Vertex Pharmaceuticals Inc

Vanguard Sells Medtronic, Cigna in 2nd Quarter Largest sales of the most recent quarter
Vanguard Health Care Fund (Trades, Portfolio) owns a portfolio composed of 74 stocks with a total value of $46.532 billion. During the second quarter the guru sold shares in the following stocks: Read more...
Weekly CFO Sells Highlight Recent sales from company chief financial officers
According to GuruFocus Insider Data, the recent CFO sells were: Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Johnson & Johnson (NYSE:JNJ). Read more...
Vertex Energy, Inc. to Release Second Quarter 2017 Financial Results on August 8, 2017
Why the Latest Vertex Pharmaceutical Data Is so Important The stock just ran more than 20% on a single development
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the biotechnology space's biggest winners this week. The company is currently trading in and around all-time highs of $160 a share, having gained more than 20% in value alone over the last couple of days. For a development stage, small-cap biotechnology stock, 20% is all in a day's work. Read more...
Spiros Segalas Gains 5 New Holdings in 2nd Quarter Guru invests in technology and pharmaceutical companies
Spiros Segalas (Trades, Portfolio)’ Harbor Capital Appreciation Fund gained five new holdings in the second quarter. They are Activision Blizzard Inc. (NASDAQ:ATVI), Crown Castle International Corp. (NYSE:CCI), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and Snap Inc. (NYSE:SNAP). Read more...
Weekly CFO Sells Highlight Insiders sell Vertex, Salesforce, Amphenol
According to GuruFocus Insider Data, the recent chief financial officer sells were Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Salesforce.com Inc. (NYSE:CRM) and Amphenol Corp. (NYSE:APH). Read more...
Galapagos NV Tests Cystic Fibrosis Treatment on First Patient The study's results will be published later this year
Galapagos NV (NASDAQ:GLPG), the Belgian clinical stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for patients with cystic fibrosis, announced Feb. 1 that the first patient received doses during the Phase 2 clinical trial, called Albatross. The study will enroll up to 35 people. Read more...
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Researchers observed a decline in sweat chloride concentration
Galapagos NV (NASDAQ:GLPG), the Belgian clinical-stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for patients affected with cystic fibrosis, announced last week the “topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.” Read more...
Piotroski F-Score in the Real World How has the F-Score fared in a real investing portfolio?
Two years ago I started a portfolio monitoring the performance of a portfolio constructed by using the Piotroski F-Score. Read more...
Testing of Treatment for Cystic Fibrosis Patients Begins Results of study will be released in the 2nd quarter of 2017
Galapagos NV (NASDAQ:GLPG), the Belgian clinical-stage biotechnology company that collaborates with AbbVie Inc. (NYSE:ABBV) on a treatment for patients affected with cystic fibrosis, announced Nov. 28 through Globe Newswire that it has started “a randomized, double-blind, placebo-controlled, single-center phase 1 study in at least 64 healthy Dutch volunteers with GLPG2737.” Read more...

Ratios

vs
industry
vs
history
PE Ratio 150.20
VRTX's PE Ratio is ranked lower than
91% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. VRTX: 150.20 )
Ranked among companies with meaningful PE Ratio only.
VRTX' s PE Ratio Range Over the Past 10 Years
Min: 25.82  Med: 125.62 Max: 560.57
Current: 150.2
25.82
560.57
Forward PE Ratio 46.73
VRTX's Forward PE Ratio is ranked lower than
82% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. VRTX: 46.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 150.20
VRTX's PE Ratio without NRI is ranked lower than
89% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. VRTX: 150.20 )
Ranked among companies with meaningful PE Ratio without NRI only.
VRTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.82  Med: 130.46 Max: 560.57
Current: 150.2
25.82
560.57
Price-to-Owner-Earnings 120.22
VRTX's Price-to-Owner-Earnings is ranked lower than
86% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. VRTX: 120.22 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VRTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.57  Med: 117.53 Max: 415.71
Current: 120.22
21.57
415.71
PB Ratio 23.05
VRTX's PB Ratio is ranked lower than
93% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. VRTX: 23.05 )
Ranked among companies with meaningful PB Ratio only.
VRTX' s PB Ratio Range Over the Past 10 Years
Min: 5.78  Med: 14.09 Max: 37.6
Current: 23.05
5.78
37.6
PS Ratio 18.00
VRTX's PS Ratio is ranked lower than
59% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. VRTX: 18.00 )
Ranked among companies with meaningful PS Ratio only.
VRTX' s PS Ratio Range Over the Past 10 Years
Min: 4.47  Med: 18.08 Max: 79.6
Current: 18
4.47
79.6
Price-to-Free-Cash-Flow 64.04
VRTX's Price-to-Free-Cash-Flow is ranked lower than
76% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. VRTX: 64.04 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VRTX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.88  Med: 63.8 Max: 1635
Current: 64.04
12.88
1635
Price-to-Operating-Cash-Flow 58.43
VRTX's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. VRTX: 58.43 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VRTX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.94  Med: 56.85 Max: 242.49
Current: 58.43
11.94
242.49
EV-to-EBIT 110.61
VRTX's EV-to-EBIT is ranked lower than
94% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. VRTX: 110.61 )
Ranked among companies with meaningful EV-to-EBIT only.
VRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -277.8  Med: -10.75 Max: 2137.9
Current: 110.61
-277.8
2137.9
EV-to-EBITDA 94.26
VRTX's EV-to-EBITDA is ranked lower than
90% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. VRTX: 94.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1067.2  Med: -11.5 Max: 297.8
Current: 94.26
-1067.2
297.8
EV-to-Revenue 17.87
VRTX's EV-to-Revenue is ranked lower than
56% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. VRTX: 17.87 )
Ranked among companies with meaningful EV-to-Revenue only.
VRTX' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.2  Med: 17.2 Max: 76.5
Current: 17.87
4.2
76.5
Current Ratio 3.49
VRTX's Current Ratio is ranked lower than
56% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. VRTX: 3.49 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.6 Max: 30.95
Current: 3.49
1.14
30.95
Quick Ratio 3.34
VRTX's Quick Ratio is ranked lower than
54% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. VRTX: 3.34 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.6 Max: 30.95
Current: 3.34
1.14
30.95
Days Inventory 122.41
VRTX's Days Inventory is ranked higher than
54% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. VRTX: 122.41 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s Days Inventory Range Over the Past 10 Years
Min: 62.49  Med: 122.98 Max: 254.87
Current: 122.41
62.49
254.87
Days Sales Outstanding 42.46
VRTX's Days Sales Outstanding is ranked higher than
69% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. VRTX: 42.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.75  Med: 45.26 Max: 61.46
Current: 42.46
25.75
61.46
Days Payable 119.09
VRTX's Days Payable is ranked higher than
73% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. VRTX: 119.09 )
Ranked among companies with meaningful Days Payable only.
VRTX' s Days Payable Range Over the Past 10 Years
Min: 106.57  Med: 382.26 Max: 1204.41
Current: 119.09
106.57
1204.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
VRTX's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. VRTX: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.2  Med: -12.35 Max: -2
Current: -2
-23.2
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 703.18
VRTX's Price-to-Net-Cash is ranked lower than
100% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. VRTX: 703.18 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VRTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.55  Med: 18.85 Max: 714.27
Current: 703.18
3.55
714.27
Price-to-Net-Current-Asset-Value 68.15
VRTX's Price-to-Net-Current-Asset-Value is ranked lower than
95% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. VRTX: 68.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VRTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.16  Med: 7.42 Max: 1835.5
Current: 68.15
2.16
1835.5
Price-to-Tangible-Book 28.81
VRTX's Price-to-Tangible-Book is ranked lower than
92% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. VRTX: 28.81 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88  Med: 8.29 Max: 120.7
Current: 28.81
1.88
120.7
Price-to-Intrinsic-Value-Projected-FCF 24.10
VRTX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
85% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. VRTX: 24.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VRTX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 20.07  Med: 55.21 Max: 819.67
Current: 24.1
20.07
819.67
Price-to-Median-PS-Value 1.00
VRTX's Price-to-Median-PS-Value is ranked higher than
50% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. VRTX: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VRTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.28  Med: 1.08 Max: 4.14
Current: 1
0.28
4.14
Price-to-Graham-Number 13.87
VRTX's Price-to-Graham-Number is ranked lower than
95% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. VRTX: 13.87 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VRTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.35  Med: 11.56 Max: 40.01
Current: 13.87
2.35
40.01
Earnings Yield (Greenblatt) % 0.90
VRTX's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. VRTX: 0.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VRTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.6  Med: -3.55 Max: 5.4
Current: 0.9
-26.6
5.4

More Statistics

Revenue (TTM) (Mil) $2,131.34
EPS (TTM) $ 1.03
Beta2.10
Short Percentage of Float1.35%
52-Week Range $71.46 - 167.86
Shares Outstanding (Mil)252.12

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 2,174 2,701 3,333 4,265
EPS ($) 1.73 3.28 5.04 7.64
EPS without NRI ($) 1.73 3.28 5.04 7.64
EPS Growth Rate
(Future 3Y To 5Y Estimate)
74.98%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}